Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Niraparib”

195 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 195 results

Testing effectiveness (Phase 2)Looking for participantsNCT06180356
What this trial is testing

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Who this might be right for
Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
MedSIR 30
Testing effectiveness (Phase 2)UnknownNCT04376073
What this trial is testing

Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Jihong Liu 40
Early research (Phase 1)Ended earlyNCT03209401
What this trial is testing

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

Who this might be right for
Solid Tumor, AdultHomologous Recombination Deficiency
Georgetown University 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04592237
What this trial is testing

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
M.D. Anderson Cancer Center 120
Testing effectiveness (Phase 2)Ended earlyNCT03891576
What this trial is testing

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Mario Negri Institute for Pharmacological Research 83
Testing effectiveness (Phase 2)Active Not RecruitingNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Large-scale testing (Phase 3)UnknownNCT04679064
What this trial is testing

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Who this might be right for
Ovarian Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 427
Testing effectiveness (Phase 2)UnknownNCT05461690
What this trial is testing

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Who this might be right for
Homologous Recombination DeficiencyTriple Negative Breast Cancer
Zhejiang Cancer Hospital 50
Testing effectiveness (Phase 2)UnknownNCT04715620
What this trial is testing

Niraparib Combined With Radiotherapy in rGBM

Who this might be right for
Recurrent Glioblastoma
Tianjin Huanhu Hospital 30
Large-scale testing (Phase 3)Looking for participantsNCT05009082
What this trial is testing

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AGO Study Group 970
Not applicableStudy completedNCT04589039
What this trial is testing

Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea

Who this might be right for
Ovarian Neoplasms
Takeda 662
Testing effectiveness (Phase 2)Looking for participantsNCT04947254
What this trial is testing

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Who this might be right for
Prostate CarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8+4 more
M.D. Anderson Cancer Center 200
Testing effectiveness (Phase 2)Study completedNCT03308942
What this trial is testing

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Who this might be right for
Neoplasms
Tesaro, Inc. 53
Testing effectiveness (Phase 2)WithdrawnNCT05672095
What this trial is testing

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
City of Hope Medical Center
Testing effectiveness (Phase 2)UnknownNCT06036966
What this trial is testing

The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients

Who this might be right for
Thrombocytopenia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 34
Post-approval studies (Phase 4)UnknownNCT05187208
What this trial is testing

PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerOvarian CancerOvarian Cancer Stage III+1 more
Seoul National University Hospital 102
Testing effectiveness (Phase 2)Study completedNCT05198804
What this trial is testing

Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal Carcinoma+1 more
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc 117
Testing effectiveness (Phase 2)Study completedNCT04313504
What this trial is testing

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Who this might be right for
Head and Neck Cancer
Trisha Wise-Draper 10
Testing effectiveness (Phase 2)Study completedNCT03759587
What this trial is testing

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 19
Testing effectiveness (Phase 2)Looking for participantsNCT05718323
What this trial is testing

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Who this might be right for
SCLC,Extensive StageSLFN11-positive
ETOP IBCSG Partners Foundation 44
Load More Results